Wall Street brokerages expect Acorda Therapeutics Inc (NASDAQ:ACOR) to announce $26.16 million in sales for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Acorda Therapeutics’ earnings, with estimates ranging from $7.80 million to $39.70 million. Acorda Therapeutics posted sales of $153.30 million during the same quarter last year, which suggests a negative year-over-year growth rate of 82.9%. The business is scheduled to report its next earnings results on Thursday, August 1st.
On average, analysts expect that Acorda Therapeutics will report full year sales of $131.45 million for the current fiscal year, with estimates ranging from $87.60 million to $170.00 million. For the next financial year, analysts anticipate that the company will post sales of $168.36 million, with estimates ranging from $121.20 million to $248.90 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Acorda Therapeutics.
Acorda Therapeutics (NASDAQ:ACOR) last released its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.51. Acorda Therapeutics had a positive return on equity of 9.34% and a negative net margin of 1.40%. The company had revenue of $44.14 million during the quarter, compared to analyst estimates of $35.14 million. During the same quarter in the previous year, the company posted $0.14 EPS. Acorda Therapeutics’s revenue for the quarter was down 58.4% on a year-over-year basis.
ACOR traded down $0.01 during midday trading on Friday, reaching $6.89. 458,780 shares of the company’s stock traded hands, compared to its average volume of 889,623. The firm has a fifty day moving average price of $7.68. The company has a market cap of $331.62 million, a PE ratio of 3.79 and a beta of 1.15. The company has a quick ratio of 3.97, a current ratio of 4.30 and a debt-to-equity ratio of 0.66. Acorda Therapeutics has a 52 week low of $6.40 and a 52 week high of $29.75.
Institutional investors have recently bought and sold shares of the stock. Financial Gravity Wealth Inc. purchased a new stake in shares of Acorda Therapeutics in the 1st quarter worth approximately $44,000. Oppenheimer Asset Management Inc. grew its stake in shares of Acorda Therapeutics by 45.8% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 4,106 shares of the biopharmaceutical company’s stock worth $55,000 after buying an additional 1,289 shares during the last quarter. NumerixS Investment Technologies Inc purchased a new stake in shares of Acorda Therapeutics in the 4th quarter worth approximately $77,000. Piedmont Investment Advisors Inc. purchased a new stake in shares of Acorda Therapeutics in the 1st quarter worth approximately $134,000. Finally, BNP Paribas Arbitrage SA grew its stake in shares of Acorda Therapeutics by 869.8% in the 1st quarter. BNP Paribas Arbitrage SA now owns 10,241 shares of the biopharmaceutical company’s stock worth $136,000 after buying an additional 9,185 shares during the last quarter.
About Acorda Therapeutics
Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe.
Featured Story: What economic reports are most valuable to investors?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.